Qihe Biotechnology

Qihe Biotechnology is a pioneering Chinese biotechnology company specializing in the development of next-generation genome editing tools and platforms. The company is widely recognized for creating CyDENT, a strand-selective, CRISPR-free base editing system that enables precise nucleotide modifications in both nuclear and organellar genomes, such as mitochondria and chloroplasts. By utilizing protein-based deamination without the need for a guide RNA or Cas proteins, Qihe's technology addresses the limitations of traditional CRISPR systems, including delivery size constraints and off-target risks. The company's platform has significant implications for treating mitochondrial genetic diseases and advancing synthetic biology. Qihe Biotechnology operates at the intersection of protein engineering and genomic medicine to provide novel therapeutic solutions for currently untreatable genetic conditions.